All
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Report an inappropriate content
Please select one of the options below.
Not Relevant
Offensive
Adult
Child Sexual Abuse
Length
All
Short (less than 5 minutes)
Medium (5-20 minutes)
Long (more than 20 minutes)
Date
All
Past 24 hours
Past week
Past month
Past year
Resolution
All
Lower than 360p
360p or higher
480p or higher
720p or higher
1080p or higher
Source
All
Dailymotion
Vimeo
Metacafe
Hulu
VEVO
Myspace
MTV
CBS
Fox
CNN
MSN
Price
All
Free
Paid
Clear filters
SafeSearch:
Moderate
Strict
Moderate (default)
Off
Filter
Top results
16:06
GMC Launches Pertuzumab-Trastuzumab Drug Combination for Subcutaneous Use on World Cancer Day, 2024
732 views
Feb 4, 2024
Facebook
Vishwajit P RANE
0:45
Subcutaneous fat😫 #FitWithM | Piyawat Seela
987K views
2 months ago
Facebook
Piyawat Seela
Subcutaneous ROA Information
6 months ago
actualized.org
Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2 Early Breast Cancer
Jan 30, 2023
onclive.com
Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2 Breast Cancer
Mar 9, 2019
onclive.com
Dr. Hahn on the Convenience of Subcutaneous Trastuzumab/Pertuzumab in HER2 Breast Cancer
Apr 30, 2021
onclive.com
Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2 Breast Cancer
7 months ago
onclive.com
Trastuzumab Deruxtecan Enhertu 100mg
3 months ago
indiamart.com
Trastuzumab Cardiotoxicity in mBC: When to Restart HER2 Therapy? Will Stopping Trastuzumab for 1 or 2 Administrations Impact the Patient Outcome?
49 views
May 28, 2023
vumedi.com
Use of Trastuzumab Deruxtecan in Ovarian Cancer
3 months ago
onclive.com
Trastuzumab 440 Mg Injection
3 months ago
indiamart.com
Trastuzumab Deruxtecan Approval for Metastatic HER2 Bladder Cancer
235 views
7 months ago
vumedi.com
Case 1: Subcutaneous HP Therapy in HER2 Breast Cancer
May 18, 2021
targetedonc.com
DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
9 months ago
onclive.com
Pertuzumab & Trastuzumab in HER2 BC: IV vs. SQ Administration, NCCN Guidelines Recommendation, and Patient Selection
750 views
Aug 12, 2023
vumedi.com
Trastuzumab Deruxtecan for Patients With HER2 Metastatic Breast Cancer (mBC)
Nov 2, 2023
onclive.com
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)
Aug 5, 2022
mskcc.org
Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2 Breast Cancer
Oct 5, 2022
onclive.com
SABCS 2023 Insights: "HER2CLIMB-05 Trial - Tucatinib or Placebo in Combination With Trastuzumab & Pertuzumab as Maintenance Therapy for HER2 mBC"
258 views
Dec 20, 2023
vumedi.com
Trastuzumab approval is a milestone: Biocon
Dec 3, 2017
Moneycontrol
The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2 Advanced BC and Brain Mets
2 weeks ago
onclive.com
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Sep 16, 2022
onclive.com
Dr Han on the Significance of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Jul 13, 2022
onclive.com
Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial
6 months ago
onclive.com
ctDNA & Trastuzumab Deruxtecan a New Frontier in Oesophagogastric Adenocarcinoma the DECIPHER Trial
6 days ago
oncologytube.com
The Impact of Subcutaneous Option for HER2 BC
Sep 24, 2020
onclive.com
Dr. Strickler on the FDA Approval of Tucatinib Plus Trastuzumab in mCRC
Jan 19, 2023
onclive.com
Efficacy of Fixed-Dose Subcutaneous Therapy for HER2 BC
Sep 24, 2020
onclive.com
Dr Hays on the Significance of the Tucatinib/Trastuzumab Approval in HER2-Positive mCRC
May 3, 2023
onclive.com
0:09
$
Human Epithelium dermis subcutaneous hypodermis subcutaneous tissue is the innermost layer of skin in your body. The dermis is the middle layer. The epidermis is the outermost layer Skin.3D
2 months ago
shutterstock
See more videos
Feedback
Feedback